<?xml version='1.0' encoding='utf-8'?>
<document id="427826"><sentence text="Important clinical pharmacologic considerations in the use of methadone in cancer patients."><entity charOffset="62-71" id="DDI-PubMed.427826.s1.e0" text="methadone" /></sentence><sentence text="The manufacturer's recommended dose of methadone, which is 2"><entity charOffset="39-48" id="DDI-PubMed.427826.s2.e0" text="methadone" /></sentence><sentence text="5-10 mg every 3-4 hours, is excessive" /><sentence text=" Methadone has an average primary-phase half-life of 14"><entity charOffset="1-10" id="DDI-PubMed.427826.s4.e0" text="Methadone" /></sentence><sentence text="3 hours and a slower secondary-phase half-life averaging 54" /><sentence text="8 hours" /><sentence text=" Administering the recommended dose of methadone and escalating doses within 2-3 days may lead to very high plasma levels of the drug"><entity charOffset="39-48" id="DDI-PubMed.427826.s7.e0" text="methadone" /></sentence><sentence text=" In addition, factors such as drug-drug interaction and/or hepatic and renal dysfunction may affect the metabolism of methadone and result in its accumulation"><entity charOffset="118-127" id="DDI-PubMed.427826.s8.e0" text="methadone" /></sentence><sentence text=" Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively"><entity charOffset="1-10" id="DDI-PubMed.427826.s9.e0" text="Methadone" /></sentence><sentence text=" Three cases of methadone overdose are presented"><entity charOffset="16-25" id="DDI-PubMed.427826.s10.e0" text="methadone" /></sentence><sentence text="" /></document>